- Finafloxacin posters presented at ICAAC 2008, Washington DC, 27th October 2008
- European Helicobacter Study Group, 20-22 September 2007, Istanbul, Turkey
- 47th ICAAC, September 2007, Chicago, USA
- Addressing the Challenges of Natural Products Drug Discovery - Dr David Appleton
- Leveraging from Mergers and Acquisitions to Sustain Competitive Advantage
- Automated high throughput separation of crude extracts into fractions for HTS primary screening - Dr David Appleton
New Fluoroquinolone Finafloxacin HCl (FIN): Route of Synthesis, Physicochemical Characteristics and Activity under Neutral and Acid Conditions
- S-E. Wohlert, T. Jaetsch, B. Gallenkamp, H. J. Knops, N. Lui, M. Preiss, D. Haebich, H. Labischinski
Effect of pH on the In Vitro Activity of Finafloxacin against Gram-negative and Gram-positive Bacteria
- M. Kresken, B. Körber-Irrgang H. Labischinski, W. Stubbings
Antimicrobial Activity of Finafloxacin (FIN) against Helicobacter pylori In Vitro and In Vivo
- A. Buissonnière, H-O. Werling, B. Bergey, P. Lehours, W. Stubbings, H. Labischinski, F. Megraud
Comparison of Methods for Finafloxacin MIC Testing at Acidic and Neutral pH
- A. Engelhardt, A. Yusof, P. Ho, C. Johansson, K. Sjöström
MIC Testing of Helicobacter pylori using Etest® Finafloxacin and the Reference Agar Dilution Method
- A. Engelhardt, A. Yusof, P. Ho, C. Johansson, K. Sjöström
Comparative Inhibitory and Bactericidal Activities of Finafloxacin and Ciprofloxacin against Gram-Negative and Gram-Positive UTI-pathogens under Physiological Conditions and at Varying pH-values
- A. Engelhardt, A. Yusof, P. Ho, C. Johansson, K. Sjöström
Bactericidal Activity Of Finafloxacin Against Difficult To Kill Growth Forms of Escherichia coli
- C. Y. Goh, F. Goh, W. Stubbings, H. P. Kroll2, H. Labischinski
Selection and Characterisation of Finafloxacin, Ciprofloxacin and Levofloxacin Resistant Mutants of Escherichia coli
- P. Leow, W. Stubbings, H. Labischinski
Pharmacokinetics (PK) and In Vivo Efficacy of Oral Finafloxacin (FIN) and Comparators in Rodent Models of Systemic Infection
- R. Endermann, C. Ladel, W. Stubbings, H. Labischinski
In Vivo Efficacy of Finafloxacin in Difficult to Treat Animal Models of Infection
- R. Endermann, C. Ladel, W. Stubbings, H. Labischinski
Comparative Activity Between Finafloxacin (FIN) and Other Fluoroquinolones Against Bacterial and Eukaryotic Type II Topoisomerases
- M. T. Muller, W. Stubbings A. Vente
In Vitro Toxicological Profiling of Finafloxacin
- G. Schmuck, G. Wasinska-Kempka, A. Vente, H. Labischinski
A Phase I Study to Determine Safety, Tolerability and Pharmacokinetics (PK) of Finafloxacin (FIN) in Healthy Subjects
- H. Patel, A. Andresen, H-D. Heilmann, M. Seiberling, L. Lopez, R. Pokorny, H. Labischinski
Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (FIN) (800mg) in Healthy Volunteers Receiving a Single Oral Dose
- F. M. E. Wagenlehner, C. Wagenlehner, B. Blenk, H. Blenk, W. Stubbings, H. Patel, S. Schubert, A. Dalhoff, K. G. Naber
Finafloxacin HCl - a novel experimental fluoroquinolone with monotherapeutic potential for Helicobacter pylori eradication
- A.J. Bishop, H. Labischinski, W. Stubbings, A.D. Buss
Friulimicin B, a Cyclic Lipopeptide, Exhibits Potent Efficacy in a Murine Pneumococcal Pneumonia Model
- R. Endermann, A. Vente, H. Labischinski
Friulimicin B Shows Good Efficacy in a Staphylococcal Murine Abscess Infection
- H. Labischinski, M. Glenschek-Sieberth, R. Endermann
Determination of the Predictive PK/PD Parameter for the Efficacy of Friulimicin B in a Murine Staphylococcal Thigh Muscle Infection
- M. Glenschek-Sieberth, S. Pelzer, H. Labischinski, J. Schumacher, R. Endermann
Comparative Analysis of the Bactericidal Activities of Friulimicin B, Daptomycin, Tigecycline, and Vancomycin against Difficult to Treat Isolates of S. aureus and S. pneumoniae
- S. Schubert, A. Dalhoff, S. Pelzer, H. Labischinski
Activity of Friulimicin B Against Glycopeptide and Daptomycin Non-susceptible S. aureus
- P. McGhee, T. Bogdanovich, K. Credito, S. Pelzer, H. Priefert, H. Labischinski, P.C. Appelbaum
Resistance Studies with Friulimicin B and Daptomycin
- W. Stubbings, W. Wu, H. Priefert, S. Pelzer, A. Vente, M. Everett, H. Labischinski
Activity of Friulimicin B and Five Other Antimicrobial Agents against 179 Gram-Positive Obligatory Anaerobic Bacteria
- R. Schaumann, D. Adler, S. Pelzer, H. Labischinski, A. C. Rodloff
Comparative in vitro Activity of the Novel Lipopeptide Friulimicin B with Daptomycin; the Effect of Inoculum, Pulmonary Surfactant and Calcium
- H. Priefert, L. Bylund, S. Pelzer, A. Vente, H. Labischinski
Comparative In Vitro Activities of the Novel Antibacterial Friulimicin B and Other Antibacterial Agents Against Selected Aerobic Gram-positive Bacteria
- M. Kresken, J. Brauers, B. Körber-Irrgang, H. Labischinski, S. Pelzer
Distinct Mode of Action of the Lipopeptide Antibiotic Friulimicin B and the Lipodepsipeptide Daptomycin: A Proteomic Study
- D. Zuehlke, B. Voigt, M. Hecker, S. Jordan, T. Mascher, S. Pelzer, H. Labischinski
Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol-Phosphate
- T. Schneider, K. Gries, I. Wiedemann, S. Pelzer, H. Labischinski, H. G. Sahl
Pan-Asian Network for Neglected Diseases Annual Meeting, June 2007, Shanghai
Drug Development Asia Summit 2007, June 2007